Published in N Engl J Med on February 02, 2006
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med (2009) 12.92
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02
Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol (2010) 1.97
Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol (2011) 1.97
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2011) 1.82
Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging (2012) 1.75
Standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases. Eur J Nucl Med Mol Imaging (2012) 1.53
Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT. Med Phys (2010) 1.49
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res (2009) 1.47
Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. Eur J Nucl Med Mol Imaging (2014) 1.43
Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med (2008) 1.40
Sources of bias for authors of clinical practice guidelines. CMAJ (2006) 1.30
Stable isotope-resolved metabolomics and applications for drug development. Pharmacol Ther (2011) 1.29
Impact of [¹⁸F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology. Eur J Nucl Med Mol Imaging (2011) 1.28
Molecular imaging for personalized cancer care. Mol Oncol (2012) 1.28
Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol (2011) 1.21
How to study optimal timing of PET/CT for monitoring of cancer treatment. Am J Nucl Med Mol Imaging (2011) 1.19
"State of the art" in liver resection and living donor liver transplantation: a worldwide survey of 100 liver centers. World J Surg (2009) 1.18
A computational pipeline for quantification of pulmonary infections in small animal models using serial PET-CT imaging. EJNMMI Res (2013) 1.17
PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol (2006) 1.16
Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer (2008) 1.14
Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle (2013) 1.14
The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging (2008) 1.10
The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol (2008) 1.07
18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Int J Clin Oncol (2011) 1.07
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget (2014) 1.06
Molecular imaging for cancer diagnosis and surgery. Adv Drug Deliv Rev (2013) 1.04
[18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol (2011) 1.04
Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proc Natl Acad Sci U S A (2014) 1.04
Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. Haematologica (2010) 1.03
Design considerations for using PET as a response measure in single site and multicenter clinical trials. Acad Radiol (2011) 1.02
Joint segmentation of anatomical and functional images: applications in quantification of lesions from PET, PET-CT, MRI-PET, and MRI-PET-CT images. Med Image Anal (2013) 1.02
Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging (2011) 1.01
Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection. Eur J Nucl Med Mol Imaging (2013) 1.01
A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res (2010) 1.00
Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer. BMC Cancer (2008) 0.99
Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma (2011) 0.97
Predictive and prognostic value of FDG-PET. Cancer Imaging (2008) 0.96
Growth in the use of PET for six cancer types after coverage by medicare: additive or replacement? J Am Coll Radiol (2012) 0.95
Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer. Ann Oncol (2009) 0.95
Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy. Eur J Nucl Med Mol Imaging (2012) 0.95
Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol (2008) 0.95
18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging (2011) 0.92
PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). J Thorac Dis (2014) 0.91
Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging (2008) 0.91
Impact of PET-CT on primary staging and response control on multimodal treatment of esophageal cancer. World J Surg (2011) 0.91
Animal models of osteoarthritis: classification, update, and measurement of outcomes. J Orthop Surg Res (2016) 0.90
Positron emission tomography imaging approaches for external beam radiation therapies: current status and future developments. Br J Radiol (2011) 0.90
Novel molecular and nanosensors for in vivo sensing. Theranostics (2013) 0.89
Molecular imaging of therapy response with (18)F-FLT and (18)F-FDG following cyclophosphamide and mTOR inhibition. Am J Nucl Med Mol Imaging (2011) 0.89
State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET. Front Med (Lausanne) (2015) 0.89
Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture. Oncotarget (2014) 0.89
Incidental colonic 18F-fluorodeoxyglucose uptake: do we need colonoscopy for patients with focal uptake confined to the left-sided colon? Dig Dis Sci (2012) 0.88
Immuno-positron emission tomography in cancer models. Semin Nucl Med (2010) 0.88
Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET. Eur J Nucl Med Mol Imaging (2010) 0.87
Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT. BMC Res Notes (2011) 0.87
Response assessment in metronomic chemotherapy: RECIST or PERCIST? Indian J Nucl Med (2014) 0.87
Clinical use of (11)C-methionine and (18)F-FDG-PET for germinoma in central nervous system. Ann Nucl Med (2013) 0.87
Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol (2007) 0.86
Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis. Br J Radiol (2012) 0.86
The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging (2013) 0.85
Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection. BMC Cancer (2011) 0.85
Multiple myeloma. Cancer Imaging (2010) 0.85
Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study. Radiat Oncol (2014) 0.85
18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors. Clin Cancer Res (2013) 0.84
Early treatment response monitoring using 2-deoxy-2-[ 18F]fluoro-D-glucose positron emission tomography imaging during fractionated radiotherapy of head neck cancer xenografts. Biomed Res Int (2014) 0.84
FDG PET/CT Response Assessment Criteria for Patients with Hodgkin's and Non-Hodgkin's Lymphoma at End of Therapy: A Multiparametric Approach. Nucl Med Mol Imaging (2015) 0.84
Novel positron emission tomography tracer distinguishes normal from cancerous cells. J Biol Chem (2011) 0.83
Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study. NMR Biomed (2014) 0.83
Multiple myeloma: a review of imaging features and radiological techniques. Bone Marrow Res (2011) 0.82
DOI-based reconstruction algorithms for a compact breast PET scanner. Med Phys (2011) 0.82
Outcome after Discontinuing Long-Term Benzimidazole Treatment in 11 Patients with Non-resectable Alveolar Echinococcosis with Negative FDG-PET/CT and Anti-EmII/3-10 Serology. PLoS Negl Trop Dis (2015) 0.82
Visualizing cancer and immune cell function with metabolic positron emission tomography. Curr Opin Genet Dev (2010) 0.82
How fibrosis influences imaging and surgical decisions in pancreatic cancer. Front Physiol (2012) 0.82
Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. Radiology (2016) 0.81
Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks. PLoS One (2015) 0.81
Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging (2016) 0.81
Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring. Front Oncol (2016) 0.81
Optimisation of whole-body PET/CT scanning protocols. Biomed Imaging Interv J (2007) 0.81
Assessment of early tumor response to cytotoxic chemotherapy with dynamic contrast-enhanced ultrasound in human breast cancer xenografts. PLoS One (2013) 0.81
Prognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis. Cancer Imaging (2015) 0.81
Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose? Eur J Nucl Med Mol Imaging (2006) 0.81
Application of FDG-PET/CT in Radiation Oncology. Front Oncol (2013) 0.81
Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy. Eur Radiol (2013) 0.80
Paraganglioma syndrome type 1 in a patient with Carney-Stratakis syndrome. Nat Rev Endocrinol (2010) 0.80
18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results. Eur J Nucl Med Mol Imaging (2010) 0.80
Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy. Int J Clin Oncol (2011) 0.80
Influence of (11)C-choline PET/CT on radiotherapy planning in prostate cancer. Rep Pract Oncol Radiother (2014) 0.80
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging (2017) 0.78
Effects of ROI Placement on PET-Based Assessment of Tumor Response to Therapy. Int J Mol Imaging (2013) 0.78
Fusion of [(18)F]FDG PET with fluorescence diffuse optical tomography to improve validation of probes and tumor imaging. Mol Imaging Biol (2013) 0.78
The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer. J Cancer Res Clin Oncol (2011) 0.78
Functional imaging in lung cancer. Clin Physiol Funct Imaging (2013) 0.78
The timing of adoption of positron emission tomography: a real options approach. Health Care Manag Sci (2009) 0.77
PET imaging of apoptosis in tumor-bearing mice and rabbits after paclitaxel treatment with (18)F(-)Labeled recombinant human His10-annexin V. Am J Nucl Med Mol Imaging (2014) 0.77
Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy. Br J Clin Pharmacol (2006) 0.77
Nanoparticle-facilitated functional and molecular imaging for the early detection of cancer. Front Mol Biosci (2014) 0.77
Is early response by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography a predictor of long-term outcome in patients with metastatic colorectal cancer? J Gastrointest Oncol (2016) 0.76
2-deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology. World J Radiol (2014) 0.76
New axillary lymph nodal F-18 fluoro-deoxy glucose uptake in an interim positron emission tomography scan - not always a sign of disease progression. Indian J Nucl Med (2011) 0.76
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol (2014) 6.61
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol (2013) 2.50
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol (2008) 2.32
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood (2002) 2.28
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer (2010) 2.19
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol (2011) 2.19
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood (2008) 2.18
The role of FDG-PET scans in patients with lymphoma. Blood (2007) 2.14
Monoclonal antibodies in advanced B-cell lymphomas. Oncology (Williston Park) (2010) 2.05
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol (2008) 2.05
The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res (2005) 1.97
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma (2008) 1.91
Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol (2008) 1.87
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol (2005) 1.84
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 1.77
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood (2013) 1.72
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol (2009) 1.61
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma (2007) 1.55
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood (2011) 1.55
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica (2011) 1.48
Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement. Am J Hematol (2004) 1.47
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma (2011) 1.44
BEACOPP or no BEACOPP? Lancet Oncol (2013) 1.39
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol (2012) 1.28
Role of positron emission tomography in lymphoma. J Clin Oncol (2005) 1.26
Implementing an expressive writing study in a cancer clinic. Oncologist (2008) 1.25
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol (2012) 1.17
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma (2009) 1.10
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma (2007) 1.08
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol (2014) 1.07
Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging (2014) 1.06
The sarcoid-lymphoma syndrome. Clin Lymphoma Myeloma Leuk (2010) 1.06
Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood (2002) 0.91
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol (2013) 0.91
Hodgkin lymphoma: protecting the victims of our success. J Clin Oncol (2012) 0.91
Mantle cell lymphoma: clinicopathologic features and treatments. Oncology (Williston Park) (2003) 0.88
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica (2011) 0.86
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clin Cancer Res (2013) 0.86
Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment. Clin Adv Hematol Oncol (2013) 0.86
Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program (2002) 0.85
Hematology: The case against rituximab maintenance. Nat Rev Clin Oncol (2009) 0.84
Histiocytic sarcoma transdifferentiated from follicular lymphoma presenting as a cutaneous tumor. J Cutan Pathol (2011) 0.84
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer (2013) 0.83
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J Hematol Oncol (2014) 0.82
State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response". Front Oncol (2013) 0.81
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma (2013) 0.81
Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol (2003) 0.81
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. Leuk Lymphoma (2012) 0.80
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma. Clin Adv Hematol Oncol (2008) 0.80
Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma (2014) 0.80
The current status and future impact of targeted therapies in non-Hodgkin lymphoma. Expert Rev Hematol (2013) 0.80
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma (2014) 0.79
Novel therapies for chronic lymphocytic leukemia. Blood Rev (2004) 0.78
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol (2008) 0.78
Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma. Future Oncol (2012) 0.78
Pre- and post-treatment evaluation of non-Hodgkin's lymphoma. Best Pract Res Clin Haematol (2002) 0.78
Resolution of lymphoma-associated open-angle glaucoma by rituximab. J Glaucoma (2011) 0.78
Time to remember to forget dose-intensification in lymphoma. J Clin Oncol (2011) 0.78
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid (2002) 0.78
Bendamustine: role and evidence in lymphoma therapy, an overview. Leuk Lymphoma (2014) 0.78
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer (2006) 0.78
Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma (2006) 0.77
Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams. J Clin Oncol (2005) 0.77
Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Expert Rev Anticancer Ther (2010) 0.77
CHOP plus rituximab--balancing facts and opinion. N Engl J Med (2002) 0.77
The optimal management of follicular lymphoma: an evolving field. Drugs (2013) 0.77
Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. Clin Adv Hematol Oncol (2010) 0.76
Resveratrol and cancer prevention. Clin Adv Hematol Oncol (2009) 0.76
Reply to M.C. Chamberlain. J Clin Oncol (2014) 0.75
Role of bendamustine in the treatment of chronic lymphocytic leukemia. Onco Targets Ther (2009) 0.75
Clinical trials referral resource. Targeted therapy in squamous cell cancers of the head and neck. Oncology (Williston Park) (2002) 0.75
Waiting is the hardest part. J Clin Oncol (2012) 0.75
Hematology: Rituximab for follicular lymphoma: maintaining an open mind. Nat Rev Clin Oncol (2011) 0.75
Small molecules, big challenges. Oncology (Williston Park) (2015) 0.75
Letter from the editor. Clin Adv Hematol Oncol (2004) 0.75
Letter from the editor. Clin Adv Hematol Oncol (2012) 0.75
Risky management. Clin Adv Hematol Oncol (2006) 0.75
We need the Annual Oncology Awards. Clin Adv Hematol Oncol (2006) 0.75
Although many of the items are natural products, we do not know what harm they might cause in the often excessive quantities that are recommended. Clin Adv Hematol Oncol (2007) 0.75
Bendamustine in the treatment of hematologic malignancies. Introduction. Semin Oncol (2002) 0.75
Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra). Oncology (Williston Park) (2002) 0.75
Recent developments in the treatment of CLL. Clin Adv Hematol Oncol (2008) 0.75
The new and ever changing PhRMA guidelines are impeding productive relationship. Clin Adv Hematol Oncol (2009) 0.75
The Peoria Principle. Clin Adv Hematol Oncol (2004) 0.75
The gift that keeps on giving. Clin Adv Hematol Oncol (2006) 0.75
Clinical trials referral resource. Current clinical trials in neuroblastoma. Oncology (Williston Park) (2002) 0.75
Expanding our mission: Clinical Lymphoma, Myeloma & Leukemia. Clin Lymphoma Myeloma (2009) 0.75
Most important accomplishments. Clin Adv Hematol Oncol (2008) 0.75
Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer. Oncology (Williston Park) (2002) 0.75
CT/PET scan. Clin Adv Hematol Oncol (2005) 0.75
Highlights of the 2008 International Conference on Malignant Lymphoma. Clin Lymphoma Myeloma (2008) 0.75
An oncoethical issue. Clin Adv Hematol Oncol (2006) 0.75